Ligand Pharmaceuticals (LGND) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LGND shares.
View LGND analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued twelve-month price objectives for Ligand Pharmaceuticals' stock. Their LGND share price forecasts range from $90.00 to $144.00. On average, they predict the company's stock price to reach $112.25 in the next year. This suggests a possible upside of 52.3% from the stock's current price.
View analysts price targets for LGND or view top-rated stocks among Wall Street analysts.

Ligand Pharmaceuticals' stock was trading at $66.80 at the beginning of the year. Since then, LGND shares have increased by 10.3% and is now trading at $73.70.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our LGND earnings forecast.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced its earnings results on Thursday, May, 4th. The biotechnology company reported $2.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.89 by $1.39. The biotechnology company had revenue of $43.98 million for the quarter, compared to the consensus estimate of $33.55 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 3.44% and a net margin of 11.00%. The company's quarterly revenue was up 20.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.15 earnings per share.

ETFs with the largest weight of Ligand Pharmaceuticals (NASDAQ:LGND) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Franklin Genomic Advancements ETF (HELX) and Pacer US Small Cap Cash Cows 100 ETF (CALF).

Ligand Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share guidance of $4.60-$4.75 for the period, compared to the consensus earnings per share estimate of $3.52. The company issued revenue guidance of $124.00 million-$128.00 million, compared to the consensus revenue estimate of $128.57 million.

1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Ligand Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.52%), Macquarie Group Ltd. (4.74%), Macquarie Group Ltd. (4.74%), State Street Corp (3.74%), Villere ST Denis J & Co. LLC (2.80%) and Dimensional Fund Advisors LP (2.74%). Insiders that own company stock include Andrew Reardon, Charles S Berkman, John L Higgins, John W Kozarich, Matthew W Foehr, Octavio Espinoza, Stephen L Sabba and Todd C Davis.
View institutional ownership trends.

Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LGND stock can currently be purchased for approximately $73.70.

Ligand Pharmaceuticals (NASDAQ:LGND) has a market capitalization of $1.27 billion and generates $196.24 million in revenue each year. The biotechnology company earns $-33,360,000.00 in net income (profit) each year or $1.26 on an earnings per share basis.

The company employs 154 workers across the globe.

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The official website for the company is www.ligand.com. The biotechnology company can be reached via phone at (858) 550-7500, via email at investors@ligand.com, or via fax at 858-550-1826.